Editas Medicine, INC DEF 14A proxy statements
Proxy statements, covering the matters put to shareholders at the annual meeting — board elections, auditor ratification and executive pay.
NASDAQ
Editas Medicine, Inc. has announced its 2026 Annual Meeting of Stockholders, scheduled for June 17, 2026, to elect directors, approve executive compensation, and ratify auditor appointment.
NASDAQ
Editas Medicine, Inc. has filed a definitive proxy statement with the SEC.
NASDAQ
DEF: Editas Medicine Proposes Stock Incentive Plan Amendment and Share Increase at 2025 Annual Meeting
Editas Medicine is seeking stockholder approval for an amended stock incentive plan and an increase in authorized shares at its upcoming 2025 annual meeting.
NASDAQ
Editas Medicine, Inc. has filed a definitive proxy statement with the SEC.
NASDAQ
Editas Medicine will hold its 2024 Annual Meeting of Stockholders virtually on May 30, 2024, to vote on director elections, executive compensation, and auditor ratification.